{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-117828","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.232563+00:00","generated_at":"2026-05-16T15:16:23.835960+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"INmune Bio corrects CEO/CFO base salaries and CEO option grant in employment agreements","bullets":["CEO David Moss base salary corrected to $454,000 per annum; option grant corrected to 750,000 shares.","CFO Cory Ellspermann base salary corrected to $240,000 per annum.","Amendments effective retroactively to November 26, 2025, to fix clerical errors in original agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-117828","json":"https://secwatch.observer/filing/0001213900-25-117828.json","markdown":"https://secwatch.observer/filing/0001213900-25-117828.md","text":"https://secwatch.observer/filing/0001213900-25-117828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117828/0001213900-25-117828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117828/ea0268270-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:16:23.835960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}